Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Tallal Younis; Chris Skedgel

doi:10.2165/11588350-000000000-00000

Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	361-365
Number of pages	5
Journal	PharmacoEconomics
Volume	29
Issue number	5
DOIs	https://doi.org/10.2165/11588350-000000000-00000
Publication status	Published - 2011
Externally published	Yes

Keywords

Cost-effectiveness
Cost-utility
Early-breast-cancer treatment
Trastuzumab therapeutic use

ASJC Scopus subject areas

Pharmacology
Health Policy
Public Health, Environmental and Occupational Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2165/11588350-000000000-00000

Cite this

@article{9aa8366bfe874f37918a2a644aac174d,

title = "Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial",

keywords = "Cost-effectiveness, Cost-utility, Early-breast-cancer treatment, Trastuzumab therapeutic use",

author = "Tallal Younis and Chris Skedgel",

year = "2011",

doi = "10.2165/11588350-000000000-00000",

language = "English",

volume = "29",

pages = "361--365",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "5",

}

TY - JOUR

T1 - Adjuvant trastuzumab for breast cancer

T2 - Uncertainties in clinical and economic evidence following early stopping of the HERA trial

AU - Younis, Tallal

AU - Skedgel, Chris

PY - 2011

Y1 - 2011

KW - Cost-effectiveness

KW - Cost-utility

KW - Early-breast-cancer treatment

KW - Trastuzumab therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=79955052041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955052041&partnerID=8YFLogxK

U2 - 10.2165/11588350-000000000-00000

DO - 10.2165/11588350-000000000-00000

M3 - Comment/debate

C2 - 21504237

AN - SCOPUS:79955052041

SN - 1170-7690

VL - 29

SP - 361

EP - 365

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 5

ER -

Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this